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Environmental carcinogens, such as polycyclic aromatic hydrocarbons (PAHs), require metabolic
activation to DNA-reactive metabolites in order to exert their tumorigenic effects. Benzo[a]pyrene (B[a]P),
a prototypic PAH, is metabolized by cytochrome P450 (P450) 1A1/1B1 and epoxide hydrolase to (-)-
B[a]P-7,8-dihydro-7,8-diol (B[a]P-7,8-dihydrodiol). B[a]P-7,8-dihydrodiol then undergoes further P4501A1/
1B1-mediated metabolism to the ultimate carcinogen, (+)-anti-7,8-dihydroxy-9,10-epoxy-7,8,9,10-
tetrahydro-B[a]P (B[a]PDE), which forms DNA-adducts primarily with 2′-deoxyguanosine (dGuo) to
form (+)-anti-trans-B[a]PDE-N2-dGuo (B[a]PDE-dGuo) in DNA. Pretreatment of cells with 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) is known to induce P4501A1/1B1 mRNA expression through the
aryl hydrocarbon receptor (AhR) pathway. This causes increased B[a]PDE-dGuo formation in liver cells.
In contrast, TCDD induction of H358 lung cells surprisingly caused a decrease in (-)-B[a]P-7,8-
dihydrodiol-mediated (+)-B[a]PDE-dGuo adduct formation when compared with the non-TCDD-induced
cells. Furthermore, treatment of the TCDD-induced cells with (()-B[a]PDE also resulted in decreased
(+)-B[a]PDE-dGuo adduct formation when compared with the non-TCDD-induced cells. These data
suggested that it was a detoxiﬁcation pathway that had been up-regulated rather than an activation pathway
that had been down-regulated. LC-MS was used to analyze B[a]PDE-dGuo and B[a]PDE-GSH-adducts
in H358 lung and HepG2 liver cells. There was a signiﬁcant increase in the (-)-B[a]PDE-GSH-adduct
with high enantiomeric excess after treatment of the TCDD-induced H358 cells with (()-B[a]PDE when
compared with the noninduced cells. This could explain why increased activation of (-)-B[a]P-7,8-
dihydrodiol through TCDD up-regulation of P4501A1/1B1 did not lead to increased (+)-B[a]PDE-dGuo
adducts in the H358 lung cells. In addition, TCDD did not induce B[a]PDE-GSH-adduct formation in
HepG2 liver cells. (()-B[a]PDE-GSH-adducts were formed at much lower levels in both TCDD-induced
and noninduced HepG2 cells when compared with (-)-B[a]PDE-GSH-adducts in the H358 lung cells.
Therefore, our study has revealed that there is a subtle balance between activation and detoxiﬁcation of
B[a]P in lung-derived compared with liver-derived cells and that this determines how much DNA damage
occurs.
Introduction
Polycyclic aromatic hydrocarbons (PAHs
1) are ubiquitous
environmental pollutants. They are formed through the combus-
tion of coal, oil, gas, wood, garbage, or other organic substances,
including tobacco and charbroiled meat (1-4). Exposure to
PAHs occurs primarily through environmental pollutants includ-
ing mainstream and sidestream smoke, as well as car exhaust
emissions (5). In smokers, B[a]P levels range from 0.5 to 7.8
µg/100 cigarettes when exposure is from mainstream smoke and
from 2.5 to 19.9 µg/100 cigarettes from side-stream smoke (6).
Nonsmokers are exposed to PAHs through passive smoking,
although at much lower levels of 0.003 to 0.760 µg/m3 (6). In
addition, both smokers and nonsmokers are exposed to PAHs
through the diet and indoor/outdoor air (5, 7, 8). PAHs reaching
the lung and the systemic circulation can be activated to reactive
metabolites (7, 8), which are detoxiﬁed and excreted from the
body (9, 10). However, when the detoxiﬁcation pathways are
saturated (11), the reactive metabolites can directly and co-
valently modify DNA to form DNA-adducts or produce reactive
oxygen species that cause oxidative DNA damage (4, 12). There
is substantial evidence to suggest that PAHs are causative agents
in lung (13, 14), skin (15, 16), and bladder cancers (15, 16).
Numerous previous reports have linked B[a]P exposure with
DNA-adduct formation, which then results in genetic alterations
that contribute to the development of multistage carcinogenesis.
For example, B[a]P-adduct formation has been shown to
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formation on guanine bases in the DNA-binding domain (17).
Several pathways of B[a]P activation are known to be
important (4). However, P4501A1/1B1-mediated activation is
the most widely accepted pathway for the formation of B[a]P-
derived DNA-adducts (4). B[a]P is oxidized initially by
P4501A1/1B1, to B[a]P-7,8-oxide, which undergoes epoxide
hydrolase (EH)-mediated hydrolysis to the proximate carcinogen
(-)-B[a]P-7,8-dihydro-7,8-diol (B[a]P-7,8-dihydrodiol) (7, 8).
P4501A1 and 1B1 are considered to be the major P450s
involved in the activation of B[a]P (18, 19). Other human P450s
(including P450s 1A2, 2E1, and 3A4) have very low or
undetectable activities toward the formation B[a]P-7,8-dihy-
drodiol (18). Further activation of (-)-B[a]P-7,8-dihydrodiol
occurs through P4501A1/1B1-mediated metabolism to (+)-
B[a]PDE, the ultimate carcinogenic reactive metabolite (20).
Other isoforms, including P4501A2, are able to metabolize
B[a]P-7,8-dihydrodiol to B[a]PDE to a lesser degree (20). (+)-
B[a]PDE can be detoxiﬁed through glutathione S-transferase
(GST)-mediated GSH-adduct formation (21, 22) or through
further hydrolysis to the corresponding tetraols (23). B[a]PDE
that escapes detoxiﬁcation reacts with DNA to form adducts,
primarily at the exocyclic N2-amine of dGuo (24). In our
previous study, H358 lung cells were treated with (()-B[a]P-
7,8-dihydrodiol, and the amount of each (()-B[a]PDE-derived
DNA-adduct was quantiﬁed (4). The dGuo- and 2′-deoxyad-
enosine (dAdo)-adduct formation in the P450/AKR expressing
cells was then compared to adduct formation from B[a]P, (-)-
B[a]P-7,8-dihydrodiol, and (+)-B[a]P-7,8-dihydrodiol treatment.
These studies revealed that (+)-B[a]PDE-dGuo was the major
adduct and that in contrast to liver cells, its formation was
maximal in H358 lung cells that had not been induced with
TCDD (Scheme 1) (4).
In order to further elucidate the mechanism underlying this
paradoxical effect, we have conducted experiments to examine
the dose-response of DNA-adduct formation to (-)-B[a]P-7,8-
dihydrodiol and TCDD in H358 cells. In addition, a microarray
analysis was conducted with H358 lung cells that had been
treated with (-)-B[a]P-7,8-dihydrodiol and/or TCDD. (()-
B[a]PDE-derived GSH-adducts were analyzed in the (()-
B[a]PDE-treated TCDD-induced H358 cells to determine
whether there was increased GSH-adduct formation compared
with that in the noninduced cells. Finally, the levels of B[a]PDE-
derived GSH-adducts in H358 cells and media were compared
to levels in human liver carcinoma, HepG2, cells and media
with and without TCDD induction. Total GST activity was also
measured in H358 and HepG2 noninduced and TCDD-induced
cells.
Materials and Methods
Caution: All PAHs are potentially hazardous and should be
handled in accordance with NIH Guidelines for the Use of Chemical
Carcinogens.
Materials and Reagents. H358 and HepG2 cells were purchased
from the American Tissue Culture Collection (ATCC; Manassas,
VA). Cell culture medium and reagents were all obtained from
Invitrogen Co. (Carlsbad, CA) except for fetal bovine serum, which
was from (FBS) Hyclone (Logan, Utah). (-)-B[a]P-7,8-dihydrodiol,
(()-B[a]PDE, and TCDD were obtained from NCI Chemical
Carcinogen Standard Reference Repository (Midwest Research
Institute, Kansas City, Missouri). Equine GST, dGuo, dAdo, and
Me2SO were purchased from Sigma Aldrich (St. Louis, MO). [15N5]-
2′-dGuo was purchased from Cambridge Isotope Laboratories
(Andover, MA). [15N5]-B[a]PDE-dGuo was synthesized as de-
scribed previously (24), and the [13C2]-B[a]P-7,8-dihydrodiol
internal standard was synthesized by Dr. R. Harvey. The purity
and identity of all B[a]P metabolites was established by LC-MS
as previously described (24, 25). Ammonium acetate and formic
acid were HPLC grade, and the methanol was Optima grade (Fisher
Scientiﬁc, Waltham, MA). All water was puriﬁed through a Milli-Q
reverse osmosis system (Millipore, Billerica, MA).
Preparation of Authentic (()-B[a]PDE-GSH-Adducts. The
GSH-adducts were prepared by a modiﬁcation of the method
described previously (25). Brieﬂy, (()-B[a]PDE (200 µg) was
incubated for 1 h with equine GST (100 units) and GSH (4 mM)
in 100 mM potassium phosphate buffer (pH 6.5) at 37 °C. The
(-)-B[a]PDE-GSH-adduct eluted at an earlier retention time than
the (+)-B[a]PDE-GSH-adduct on the YMC ODS-AQ column under
the conditions described below. This is similar to the elution proﬁle
described previously (26). Product ion spectra from collision-
induced dissociation (CID) of m/z 610 (B[a]PDE-GSH, MH+) were
essentially identical for the two enantiomers: m/z 592 (MH+-H2O),
m/z 574 (MH+-2H2O), m/z 445 (MH+-H2O-a ˜-Glu), m/z 427 (MH+-
2H2O-a ˜Glu), m/z 308 (GSH+H+), m/z 303 (B[a]PDE+H+), m/z
285 (B[a]PDE+H+-H2O), and m/z 257(B[a]PDE+H+-H2O-CO).
Cell Culture. Human bronchoalveolar H358 cells (ATCC #CRL-
5807) were maintained in RPMI 1640 nutrient mixture with 10%
heat-inactivated FBS, 2 mM L-glutamine, 100 units/mL penicillin,
and 100 µg/mL streptomycin. Human liver carcinoma HepG2 cells
(ATCC #HB-8065) were maintained in Eagle’s Minimum Essential
Medium with 10% heat-inactivated FBS, 100 units/mL penicillin,
and 100 µg/mL streptomycin. Cells were incubated at 37 °Ci na
humidiﬁed atmosphere containing 5% CO2 and were passaged every
3 days at a 1:3 dilution. Cultured cells with a passage number of
15 or less were used in the experiments to reduce variability during
cell culture.
(-)-B[a]P-7,8-Dihydrodiol Concentration Dependence. Con-
trol, untreated H358 cells and TCDD-induced (10 nM, 24 h) H358
cells were treated with increasing concentrations of (-)-B[a]P-7,8-
dihydrodiol in 0.3% Me2SO (0.1 µMt o2µM) or 0.3% Me2SO for
24 h. The (+)-B[a]PDE-dGuo and total DNA were then quantiﬁed
as described below.
(-)-B[a]P-7,8-Dihydrodiol Metabolism. H358 cells were treated
with 2 µM( -)-B[a]P-7,8-dihydrodiol in 0.3% Me2SO for 6 h with
and without 10 nM TCDD pretreatment in 10 mL of RPMI/FBS
medium. At 6 h, cells were collected, and the remaining (-)-B[a]P-
7,8-dihydrodiol was analyzed as described below.
Scheme 1. Metabolism of B[a]P in Human Lung Cells
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Mediated DNA-Adduct Formation. H358 cells (106/cells plate)
were pretreated in 10 mL of RPMI/FBS medium with increasing
concentrations of TCDD (0, 1, 10 nM) for 24 h before treatment
with (-)-B[a]P-7,8-dihydrodiol (5.7 µg, 2 µM ﬁnal concentration)
in 0.3% Me2SO for 24 h. The (+)-B[a]PDE-dGuo and total DNA
were then quantiﬁed as described below.
(()-B[a]PDE and TCDD Treatment. H358 cells (106/cells
plate) were treated in 10 mL RPMI/FBS medium with 2 µM( ()-
B[a]PDE (6.1 µg, 2 µM ﬁnal concentration) in 0.3% Me2SO (24
h) with or without TCDD (10 nM) pretreatment for 24 h. The (+)-
B[a]PDE-dGuo and total DNA were then quantiﬁed as described
below. Additionally, H358 and HepG2 cells (2 × 105/cells plate)
were treated in 2 mL of media with (()-B[a]PDE (12.1 µg, 20
µM ﬁnal concentration) in 0.3% Me2SO (30 min, 1, 2, 4, and 6 h)
with and without TCDD (10 nM) pretreatment for 24 h. Cells and
media were collected, and two plates were combined into one
sample for the measurement of B[a]PDE-GSH-adducts by LC-ESI-
MS/MS as described below.
LC-ESI/MRM/MS. Data for (+)-B[a]PDE-dGuo adducts were
acquired using an Agilent 1100 HPLC system (Agilent Technology,
Palo Alto, CA) equipped with a CTC autosampler (Leap Technol-
ogy, Carrboro, NC) and an MDS-Sciex API-4000 triple-quadrupole
mass spectrometer (Applied Biosystems, Foster City, CA). The
HPLC method employed a YMC J’sphere M80 column (2.0 mm
I.D. × 150 mm, 4 µm) using 5 mM NH4OAc buffer containing
0.02% formic acid as mobile phase A and methanol as mobile phase
B at a ﬂow rate of 200 µL/min. The gradient started from 49% B
to 51% B in 20 min, followed by 51% B to 65% B in 10 min, and
continued to 100% B in 5 min. The following mass spectrometer
parameters were set: collision gas (nitrogen), 10 units; curtain gas
(nitrogen), 30 units; ion source gas number 1 (nitrogen), 30 units;
ion source gas number 2 (nitrogen), 30 units; ion spray voltage,
5.0 kV; ionization temperature, 500 °C; decluster potential, 50 V;
entrance potential, 8 V; collision energy, 40 eV; and collision cell
exit potential, 22 V. MRM analyses were conducted in positive
ESI mode. The following transitions were monitored for (+)-
B[a]PDE-dGuo: m/z 570.2 (MH+,( +)-B[a]PDE-dGuo) f m/z
257.1 (MH+-dGuo-H2O-CO) and m/z 575.2 ([15N5]-B[a]PDE-dGuo)
f m/z 257.1 (MH+-[15N5]-dGuo-H2O-CO).
Data for (-)-B[a]P-7,8-dihydrodiol were also acquired using the
instrumentation described above. The HPLC method employed a
Phenomenex Luna C18(2)-ODS column (4.0 mm I.D. × 125 mm,
4 µm) using 5 mM NH4OAc buffer containing 0.1% formic acid
as mobile phase A and methanol containing 0.1% formic acid as
mobile phase B at a ﬂow rate of 300 µL/min. The gradient started
from 60% B to 70% B in 20 min, followed by 70% B to 80% B in
10 min. This was held for 20 min followed by an increase to 95%
B in 5 min. Again, this was held for 5 min before returning to
starting 60% B, held for 20 min for column equilibration. Mass
spectrometer parameters different from those used for (+)-B[a]PDE-
dGuo adducts were collision gas, 9 units; curtain gas, 10 units; ion
source gas number 2, 50 units; entrance potential, 12 V; collision
energy, 30 eV; and collision cell exit potential, 20 V. The following
transitions were monitored: for (-)-B[a]P-7,8-dihydrodiol, m/z
269.1 (MH+-H2O, (-)-B[a]P-7,8-dihydrodiol) f m/z 251.1 (MH+-
2H2O); for [13C2]-(-)-B[a]P-7,8-dihydrodiol, m/z 271.3 (MH+-
H2O), [13C2]- (-)-B[a]P-7,8-dihydrodiol) f m/z 253.3 (MH+-
2H2O).
Data for the B[a]PDE-GSH-adduct were acquired using a Waters
2690 HPLC system (Waters Co., Milford, MA) equipped with an
autosampler and a Thermo Fisher LTQ ion trap mass spectrometer
(Thermo Fisher, Mullica Hill, NJ). The HPLC method employed a
YMC ODS-AQ column (2.0 mm I.D. × 150 mm, 3 µm) using
water containing 0.1% formic acid as mobile phase A and
acetonitrile containing 0.1% formic acid as mobile phase B at a
ﬂow rate of 200 µL/min. The gradient started from 20% B to 50%
B in 8 min, followed by 50% B to 100% B in 14 min; 100% B
was held for 3 min followed by a return to starting conditions, 20%
B for 10 min. The following mass spectrometer parameters were
set: nitrogen was used for sheath (41 units) and auxiliary gas (12
units). Helium was used as the collision gas with a collision energy
of 35 eV. All analyses, full scans, product ion scans, and MRM
were conducted in positive ESI mode. The following transition was
monitored for the B[a]PDE-GSH-adduct: m/z 610.2 (MH+,B [ a]PDE-
GSH) f m/z 308.1 (GSH+H+).
Microarray Analysis. H358 cells (n ) 6 for each treatment
group) were treated with the Me2SO vehicle control for 48 h, 10
nM TCDD for 48 h, 2 µM( -)-B[a]P-7,8-dihydrodiol for 24 h, or
a combination of 10 nM TCDD and 2 µM( -)-B[a]P-7,8-
dihydrodiol for 48 and 24 h, respectively. After the allotted
treatment times, total RNA was extracted from H358 cells using
the miRNeasy protocol from Qiagen. Microarray analysis was
performed according to the Affymetrix protocol using the Affyme-
trix HuGene 1.0 array platform (Santa Clara, CA). Four samples
from each treatment category were chosen for microarray analysis.
Data analysis was performed using Partek Genomics Suite (Partek
Inc., St. Louis, MO). Subsequent visualization and ﬁltering used
Spotﬁre DecisionSite, version 9.1 (Tibco Software Inc., Palo Alto,
CA, USA). Affymetrix .cel ﬁles were imported, and Robust
Multiarray Average was performed on the microarray data yielding
log2 transformed signal intensities for each probeset on each array.
Next, the low expression probesets were ﬁltered out, retaining
probesets with log2 intensities of greater than 5 in at least 3 of the
16 samples. This left 22,136 probesets available for statistical
analysis. A one way ANOVA with 6 pairwise contrasts was then
performed yielding p-values for the ANOVA and for each of the
comparisons. Fold-change values for each of the pairwise com-
parisons were also calculated. The 6 comparisons included TCDD
vs Me2SO, diol vs Me2SO, TCDD-diol vs Me2SO, diol vs TCDD,
and TCDD-diol vs TCDD and TCDD-diol vs diol. For each
calculated p-value, a Benjamini-Hochberg step-up p-value was also
determined to assess the false discovery rate.
Quantiﬁcation of DNA-Adducts. For calibration curves of the
DNA-adducts, the four stereoisomers of authentic B[a]PDE-N2-
dGuo and B[a]PDE-[15N5]-N2-dGuo were used to make standard
mixtures of different concentrations (0.1, 0.2, 0.5, 1.0, 2.5, 5.0,
and 10.0 ng of each). The standard solutions underwent the same
sample preparation and analytical procedures as the experimental
samples described above. Calibration curves were calculated with
a linear regression analysis of the peak area ratios of standard versus
the internal standard. DNA-adduct levels were calculated by
interpolation from the calibration curve and normalized with the
total base content in each sample (4). Levels are reported as number
of (+)-B[a]PDE-dGuo adducts per 106 normal bases.
DNA Base Analysis. LC-UV chromatography for DNA base
analysis was conducted on a Hitachi Elite Lachrom HPLC system
equipped with a UV detector. The separation employed a Phenom-
enex Luna C18(2) column (4.0 mm I.D. × 125 mm, 5 µm). Solvent
A was aqueous 5 mM NH4OAc with 0.02% formic acid, and solvent
B was methanol. The ﬂow rate was 0.9 mL/min, and DNA bases
were separated isocratically at 15% B for 20 min. The UV detector
monitored the absorbance at 260 nm. For calibration curves,
solutions containing certain concentrations of authentic DNA bases
(0.0, 2.0, 5.0, 10.0, 20.0, and 50.0 µg/mL) were subjected to HPLC-
UV analysis. The injection volume was 20 µL. Calibration curves
were calculated with a linear regression analysis of the peak areas
of authentic standards. A portion of the digested sample was
subjected to the same HPLC-UV procedure for base analysis. The
DNA base level was calculated by interpolation from the calibration
curve.
GST Activity Assay. The activity of total GST was assessed in
TCDD-induced and noninduced H358 and HepG2 cells using
1-chloro,2,4-dinitrobenzene (CDNB). Induced H358 and HepG2
cells were treated with 10 nM TCDD for 24 h. Brieﬂy, 0.1 M
KH2PO4, pH 6.5, 1.0 mM CDNB, 1.0 mM GSH-, and either
GSTR-1 (1 µg) or cell lysate (25 µL) were then combined. Total
GST activity was assessed by monitoring CDNB-GSH-adduct
formation at 340 nm over 15 min, during which time adduct
formation was linear. Activity is reported in nmol/min/mg protein,
and nonenzymatic GSH-adduct formation was taken into account
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Results
TCDD Effect on (-)-B[a]P-7,8-Dihydrodiol-Mediated
DNA-Adduct Formation in Lung Cells. H358 cells were
pretreated with 10 nM TCDD for 24 h before (-)-B[a]P-7,8-
dihydrodiol treatment for 24 h. At the lowest concentration of
0.1 µM( -)-B[a]P-7,8-dihydrodiol, (+)-B[a]PDE-dGuo-adduct
levels were below the limit of detection of 10 pg on column
(Figure 1)), which was rigorously determined in our previous
study (24). The TCDD caused a signiﬁcant decrease in (+)-
B[a]PDE-dGuo adducts at each concentration of (-)-B[a]P-
7,8-dihydrodiol that was used. There was almost a 7-fold
decrease of (+)-B[a]PDE-dGuo adducts at 2 µM( -)-B[a]P-
7,8-dihydrodiol, the highest concentration that was examined
(Figure 1). There was also signiﬁcant up-regulation (p < 0.05)
of GSTM1 (1.3-fold), ALDH3A1 (2-fold), and ALDH1A3 (2.8-
fold). The increase in CYP1A1 mRNA detected by the mi-
croarray experiments was validated by quantitative PCR using
CYP1A2 as a negative control (data not shown).
(-)-B[a]P-7,8-Dihydrodiol Metabolism. Residual (-)-B[a]P-
7,8-dihydrodiol was detected in the cells by LC-MRM/MS after
6 h when 2 µM( -)-B[a]P-7,8-dihydrodiol was used with and
without 10 nM TCDD pretreatment for 24 h (Figure 2).
Quantitation using the [13C2]-(-)-B[a]P-7,8-dihydrodiol internal
standard revealed that (-)-B[a]P-7,8-dihydrodiol was metabo-
lized at a faster rate with TCDD induction.
Effect of TCDD Concentration on DNA-Adduct Forma-
tion. H358 cells were induced with different concentrations of
TCDD (0, 1, and 10 nM) for 24 and then treated with 1.0 µM
(-)-B[a]P-7,8-dihydrodiol for 24 h. There was signiﬁcant
reduction in (+)-B[a]PDE-dGuo adducts as the concentration
of TCDD used in the induction was increased from 0 nM to 1
nM and from 1 nM to 10 nM (Figure 3).
Microarray Analysis of Lung Cells Treated with TCDD
and B[a]P Metabolites. Signiﬁcant effects on P4501A1 and
P4501B1 mRNA expression were observed. None of the other
genes that have been previously associated with B[a]P metabo-
lism in the lung were signiﬁcantly up- or down-regulated.
Treatment of H358 cells with 10 nM TCDD for 48 h, resulted
in a P4501A1 superinduction of 80-fold together with a
substantial increase in P4501B1 mRNA (12-fold) (Figure 4).
The effect on P4501A1 was attenuated by the addition of (-)-
B[a]P-7,8-didhydrodiol for 24 h to a level similar to that
observed with the (-)-B[a]P-7,8-dihydrodiol alone for 24 h (16-
fold) (Figure 4). P4501B1 was induced 12-fold by TCDD
treatment for 48 h. Addition of (-)-B[a]P-7,8-dihydrodiol alone
induced P4501B1 mRNA expression 7-fold compared to that
in the Me2SO control. The addition of (-)-B[a]P-7,8-dihydrodiol
after 24 h of TCDD treatment attenuated the effect of TCDD
on CY1B1 and resulted in a 9-fold increase in P4501B1 mRNA
levels compared to that in the Me2SO control.
(()-B[a]PDE-Mediated DNA-Adduct Formation in Lung
Cells. H358 cells were treated with 2 µM( ()-B[a]PDE for 24 h.
(+)-B[a]PDE-dGuo adduct levels were 13.5 ( 1.0 adducts/106
bases (Figure 5). TCDD pretreatment for 24 h resulted in a
signiﬁcant decrease in adduct formation (p < 0.003) to 6.0 (
0.4 adducts/106 bases (Figure 5).
(()-B[a]PDE-Mediated GSH-Adduct Formation in Lung
and Liver Cells. LC-MS/MS analysis revealed an almost 10-
fold increase in intracellular (-)-B[a]PDE GSH-adduct forma-
tion in the TCDD-induced H358 lung cells (Figure 6A; intensity
3.9 × 105) compared with that in the noninduced H358 cells
(Figure 6C; intensity 4.3 × 104) aftera4hincubation. The
chromatographic peak observed at 12.4 min in Figure 6A and
Figure 1. (-)-B[a]P-7,8-dihydrodiol concentration dependence. The
levels of (+)-B[a]PDE-dGuo DNA-adducts formed in H358 cells with
increasing concentrations of (-)-B[a]P-7,8-diol (0.1, 0.5, 1.0, and 2.0
µM) in 24 h with and without 10 nM TCDD pretreatment for 24 h.
Experiments were conducted in triplicate, and the values are expressed
as the means ( SEM. B[a]PDE-dGuo levels were signiﬁcantly higher
(p < 0.05) in H358 cells not treated with TCDD.
Figure 2. LC-MRM/MS analysis of (-)-B[a]P-7,8-dihydrodiol in H358
cells. Analyses were conducted aftera6hincubation of H358 cells
treated with 2 µM( -)-B[a]P-7,8-dihydrodiol with and without 10 nM
TCDD pretreatment for 24 h. The ratio of (-)-B[a]P-7,8-dihydrodiol
to the [13C2]-B[a]P-7,8-dihydrodiol internal standard was calculated for
experiments in triplicate. Experiments were conducted in triplicate, and
the values are expressed as the means ( SEM. The ratio for H358
cells pretreated with 10 nM TCDD for 24 h was signiﬁcantly lower (p
< 0.05) than that of H358 cells that were not pretreated with TCDD.
Figure 3. TCDD concentration dependence. H358 cells were pretreated
with TCDD (0, 1.0, and 10 nM) for 24 h and treated with 1.0 µM
(-)-B[a]P-7,8-dihydrodiol for 24 h. Experiments were conducted in
triplicate, and the values are expressed as the means ( SEM. As the
concentration of TCDD increased, the level of (+)-B[a]PDE-dGuo
decreased signiﬁcantly (p < 0.05).
92 Chem. Res. Toxicol., Vol. 24, No. 1, 2011 Gelhaus et al.B was not derived from a B[a]P-GSH-adduct and therefore did
not appear in the corresponding LC-MRM/MS chromatogram
(Figure 7A). The product ion spectrum of (-)-B[a]PDE-GSH-
adduct (Figure 6B) was identical to that obtained from an
authentic standard prepared using equine GST and (()-B[a]PDE
(data not shown). LC-MRM/MS analysis showed that intracel-
lular (-)-B[a]PDE-GSH-adduct formation in TCDD-induced
H358 lung cells was almost 2 orders of magnitude greater
(Figure 7A; peak area 454,522) than (()-B[a]PDE-GSH-adduct
formation in TCDD-induced HepG2 liver cells (Figure 7C; total
peak area 5,628) aftera4hincubation. Furthermore, enanti-
oselective formation of the (-)-B[a]PDE-GSH-adduct was
observed in H358 cells (Figure 7A), whereas racemic (()-
B[a]PDE-derived GSH-adducts were formed in HepG2 cells
(Figure 7C). The product ion spectra for the (-)-B[a]PDE-GSH-
adduct (Figure 6B) and (+)-B[a]PDE-GSH-adduct (Figure 7B)
were identical to the spectra from synthesized standards (data
not shown).
LC-MRM/MS analyses conducted overa6hperiod revealed
that intracellular and extracellular (-)-B[a]PDE-GSH-adducts
were an order of magnitude higher at all time points in the
TCDD-induced H358 lung cells (Figure 8A and B) when
compared with that in the noninduced cells (Figure 9A and B).
In contrast, there was virtually no difference over a 6 h period
between intracellular and extracellular (()-B[a]PDE-GSH-
adducts in the TCDD-induced HepG2 liver cells (Figure 8C
and D) when compared with the noninduced cells (Figure 9C
and D). Therefore, TCDD induction caused an almost 2 orders
Figure 4. Microarray expression. The fold change in mRNA depending
upon the various cell treatments: DMSO, 10 nM TCDD (48 h), 2 µM
(-)-B[a]P-7,8-dihydrodiol (24 h), and 10 nM TCDD (48 h) with 2
µM( -)-B[a]P-7,8-dihydrodiol (24 h). (A) CYP1A1. (B) CYP1B1.
Figure 5. Measurement of (+)-B[a]PDE-dGuo H358 cells treated with
2 µM( ()-B[a]PDE with and without 10 nM TCDD pretreatment. (+)-
B[a]PDE-dGuo formation with TCDD-induced cells was decreased
compared with that of the noninduced cells.
Figure 6. LC-MS/MS analysis of B[a]PDE-GSH-adducts in (()-
B[a]PDE-treated H358 cells. (A) LC-MS/MS chromatogram of the
intracellular (-)-B[a]PDE-GSH-adduct in TCDD-induced H358 cells
aftera4hincubation. (B) Product ion spectrum of the (-)-B[a]PDE-
GSH-adduct (MH+, m/z 610) in TCDD-induced H358 cells. (C) LC-
MS/MS chromatogram of the intracellular (-)-B[a]PDE-GSH-adduct
in noninduced H358 cells aftera4hincubation. H358 cells pretreated
with 10 nM TCDD for 24 h had increased levels of (-)-B[a]PDE-
GSH-adducts.
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B[a]PDE-GSH-adducts in the H358 lung cells (Figure 8A and
B) when compared with that in HepG2 liver cells (Figure 8C
and D). To conﬁrm that these changes were a result of alterations
in GSTs rather than modiﬁcations in GSH biosynthesis and
utilization, the GSH/GSSG ratio was quantiﬁed by stable isotope
dilution LC-MS (27). This ratio did not change signiﬁcantly in
H358 control cells versus TCDD-induced cells, and GSH
concentrations did not change (Supporting Information, Figure 1).
GST Activity Assay. The overall activity of GSTs was
assessed in TCDD-induced and noninduced H358 and HepG2
cells. The GST activity increased modestly in H358 cells treated
with 10 nM TCDD for 24 h (Table 1). In contrast, the GST
activity in HepG2 cells was slightly lower than that found in
H358 cells and was further reduced by TCDD treatment (Table
1).
Discussion
DNA- and GSH-adduct formation was assessed in the H358
human bronchoalveolar cell line because they are known to have
basal levels of CYPs and AKRs without induction and are a
well-characterized cell model for B[a]P metabolism in the lung
(23-25, 28, 29). Similar studies were conducted in the HepG2
cell line because it has previously been employed extensively
as a model for B[a]P metabolism in the liver (30-33). Previous
studies by our group showed that (+)-B[a]PDE-dGuo adducts
were found in higher concentration in H358 parental cells not
treated with TCDD to induce P450 expression than in the
corresponding TCDD-induced cells (4). To conﬁrm these data,
we examined how the concentration of (-)-B[a]P-7,8-dihy-
drodiol affected the formation of (+)-B[a]PDE-dGuo in H358
cells. At both low and high concentrations of (-)-B[a]P-7,8-
dihydrodiol, there was an increase in DNA-adducts formed in
H358 cells when compared with that in TCDD-induced cells
(Figure 1). The TCDD-induced cells metabolized the (-)-B[a]P-
7,8-dihydrodiol more rapidly than the noninduced cells so that
it could still be detected by LC-MRM/MS in the noninduced
cells aftera6hincubation (Figure 2). Furthermore, there was
a dose-response in the ability of TCDD to reduce B[a]PDE-
dGuo formation (Figure 3).
Data obtained in lung cells greatly contrasts with that obtained
in liver cells, where there was a signiﬁcant increase in DNA-
adducts after TCDD treatment (34). The effect of TCDD has
been ascribed to the up-regulation of P4501A1/1B1 (35-38).
Therefore, our ﬁndings raised the intriguing possibility that
TCDD-induction (39) is protective against (+)-B[a]PDE-
mediated DNA damage in the lung even though P4501A1/1B1
are required for the activation of (-)-B[a]P-7,8-dihdyrodiol to
the ultimate genotoxin, (+)-B[a]PDE (18, 20).
In order to gain further insight into gene regulation, a
microarray analysis was performed in H358 cells that had been
treated with TCDD and or (-)-B[a]P-7,8-dihydrodiol. TCDD
was found previously to induce 8 genes (CYP1A1, CYP1B1,
CRYZ, GSTM1, GLRX, ALDH3, ALDH1A3, and ALDH10)
in human A549 and HPL1A lung cells through the aryl
hydrocarbon receptor (AhR) pathway (40). As was found with
A549 and HPLA1 lung cells, CYP1A1 was the major gene that
was up-regulated by TCDD in the H358 cells, followed by
CYP1B1 (Figure 4). We found that there was also signiﬁcant
up-regulation of GSTM1, ALDH3A1, and ALDH1A3. How-
ever, in contrast to the A549 and HPLA1 cells (40), up-
regulation of CRYZ, GLRX, ALDH10 was not detected in the
H358 cells. TCDD binds to the AhR, a cytosolic, ligand
activated transcription factor. The AhR is complexed with
chaperone proteins, including p23, XAP2/ARA9, and Hsp90
(41, 42). When TCDD binds to the AhR, a conformational
change occurs, which results in the loss of certain chaperone
proteins and nuclear localization (37). Once the TCDD-bound
AhR has translocated to the nucleus, it binds with the AhR
nuclear translocater. This complex then binds to consensus
nucleotide sequences, termed xenobiotic response elements
(XREs), in the 5′ untranslated region of responsive genes and
modulates the transcription of these genes.
Induction of P4501A1/1B1 by (-)-B[a]P-7,8-dihdyrodiol
(Figure 4) most likely results through the formation of the planar
metabolite B[a]P-7,8-dione formed in the AKR pathway (23).
The expression of AKRs was not signiﬁcantly (>2-fold) induced
by TCDD or (-)-B[a]P-7,8-dihydrodiol cell treatments when
compared with that of dimethylsulfoxide alone (data not shown).
However, the microarray results revealed that mRNA for
AKR1B1, 1A1, 1C1, 1C2, 7A2, and 7A3 was present in the
cells (data not shown). We previously noted that there was a
lag in the formation of (+)-B[a]PDE-dGuo adducts in H358
cells treated with B[a]P-7,8-dihydrodiol. Therefore, we suggest
that B[a]P-7,8-dihydrodiol is converted to the B[a]P-7,8-catechol
by a member of the AKR family. The catechol then undergoes
a two-electron oxidation to form the planar B[a]P-7,8-dione,
and it is most likely the metabolite to bind the AhR, thus
Figure 7. LC-MRM/MS analysis of B[a]PDE-GSH-adducts in (()-
B[a]PDE-treated H358 and HepG2 cells with 10 nM TCDD pretreat-
ment for 24 h. (A) Intracellular (-)-B[a]PDE-GSH-adducts in TCDD-
induced H358 cells aftera4hincubation. (B) Product ion spectrum of
the (+)-B[a]PDE-GSH-adduct in HepG2-induced cells (MH+, m/z 610).
(C) Intracellular (()-B[a]PDE-GSH-adducts in TCDD-induced HepG2
cells aftera4hincubation.
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for TCDD. In order to conﬁrm this protective effect, direct
B[a]PDE-mediated DNA-adduct formation was examined in the
TCDD-induced and noninduced H358 cells. This showed that
(+)-B[a]PDE-dGuo adducts were signiﬁcantly reduced in the
TCDD-treated H358 cells when compared with those in the
noninduced cells (Figure 5).
The most logical explanation for the TCDD effect on DNA-
adduct formation is that increased metabolism of (+)-B[a]PDE
had occurred. It has recently been recognized that TCDD can
up-regulate GSTs in rodent cells (43). If this occurred in human
lung cells, it could result in increased conversion of (+)-
B[a]PDE to B[a]PDE-GSH-adducts, which would decrease the
availability of (+)-B[a]PDE for DNA-adduct formation as
shown in Scheme 2. In order to test this possibility, authentic
(()-B[a]PDE-GSH-adducts were prepared and their LC-MS
characteristics determined. (()-B[a]PDE-GSH-adduct formation
was then determined in H358 and HepG2 cells and media with
or without TCDD treatment. LC-MS/MS analysis revealed that
the (-)-B[a]PDE-GSH-adduct was a signiﬁcant metabolite in
both TCDD-induced (Figure 6A) and noninduced H358 cells
(Figure 6C). However, there was an almost a 10-fold increase
in the (-)-B[a]PDE-GSH-adduct in TCDD-induced H358 cells
(Figure 6A) when compared with that in the noninduced cells
(Figure 6C). Formation of B[a]PDE-GSH-adducts in HepG2
cells (Figure 7C) also occurred, but levels were much lower
than that in H358 cells (Figure 7A). GSH-adducts once secreted
by cells are metabolized to their corresponding cysteinylglycine
adducts by γ-glutamyltranspeptidase, which is localized on the
external surface of the plasma membrane (44, 45). The loss of
the initially formed B[a]P-GSH-adducts over time observed in
the H358 and HepG2 cell media (Figures 8 and 9) is in keeping
with this expected pathway of metabolism. However, the
formation of the B[a]P-cysteinylglycine-adducts or their further
dipeptidase and N-acetyl-cysteine-transferase-mediated conver-
sion to cysteine (45) and N-acetylcysteine metabolites (46) was
not monitored in the present study.
Analysis of HepG2 cells and media revealed the formation
of the (()-B[a]PDE-GSH-adduct rather than the (-)-enanti-
omer, suggesting that different GSTs are responsible for GSH-
adduct formation in lung cells compared with that in liver cells.
GSTπ, an abundant GST in the lung but not in hepatocytes (47),
efﬁciently converts (+)-B[a]PDE into (-)-B[a]PDE-GSH
(Scheme 1) (26, 48, 49). GSTR and GSTµ show much lower
enantioselectivity for (+)-B[a]PDE, and in addition, GSTµ is
primarily expressed in the liver rather than the lung (50, 51).
Previous studies have shown that GSTπ-expressing cell lines
are protected against (+)-B[a]PDE-mediated DNA damage
(52, 53). Therefore, it is likely that GSTR and/or GSTµ are
responsible for the racemic formation of B[a]PDE-GSH-adducts
in the liver-derived HepG2 cells, whereas GSTπ is responsible
for enantioselective GSH-adduct formation in the lung-derived
H358 cells. Intracellular and extracellular (-)-B[a]PDE-GSH-
adduct levels in our study were an order of magnitude higher
in the TCDD-induced H358 lung cells (Figure 8A and B) when
compared with that in the noninduced cells (Figure 9A and B),
whereas TCDD induction (Figure 8C and D) had little effect
on the HepG2 liver cells when compared with that in the
Figure 8. B[a]PDE-GSH-adducts in H358 and HepG2 cells and media after TCDD induction. H358 and HepG2 cells were treated with (()-
B[a]PDE for 30 min, 1, 2, 4, and 6 h with 10 nM TCDD pretreatment for 24 h and GSH-adducts quantiﬁed by LC-MS. (A) Intracellular (()-
B[a]PDE-GSH-adducts in H358 cells. (B) Intracellular (()-B[a]PDE-GSH-adducts in HepG2 cells. (C) (()-B[a]PDE-GSH-adducts in H358 cell
media. (D) (()-B[a]PDE-GSH-adducts in HepG2 cell media. Analyses were conducted in duplicate, and the mean values are shown. (-)-B[a]PDE-
GSH-adduct (solid triangle); (+)-B[a]PDE-GSH-adduct (solid square).
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stark contrast between the TCDD-induced H358 lung and
HepG2 liver cells. Intracellular and extracellular (-)-B[a]PDE-
GSH-adduct levels were almost 2 orders of magnitude higher
in the TCDD-induced H358 cells (Figure 8A and B) when
compared with the (()-B[a]PDE-GSH-adduct levels in the
induced HepG2 cells (Figure 8C and D).
These ﬁndings are consistent with lung cell speciﬁc TCDD-
mediated up-regulation of GST isoforms that have enantiose-
lectivity similar to that found for GSTπ-mediated detoxiﬁcation
of (+)-B[a]PDE (26, 48, 49) or induction of a post-translational
modiﬁcation that increases the activity of GSTπ. However, we
were unable to detect up-regulation of any GSTs with the
required stereoselectivity. It is noteworthy that GSTπ can
undergo epidermal growth fact receptor-mediated phosphory-
lation at Tyrosine-7 and Tyrosine-198 (54). In addition, GSTπ
is phosphorylated by the action of serine/threonine kinases,
protein kinase C, and protein kinase A (55). Furthermore,
epidermal growth fact receptor-mediated phosphorylation of
Tyrosine-7 and Tyrosine-198 was found to increase the activity
of GSTπ through a conformational change in the enzyme (54).
Therefore, there is a body of literature to suggest that the
substantial increase in GSH-adduct formation we observed could
have arisen through a TCDD-mediated increase in the phos-
phorylation of GSTπ with a concomitant increase in its activity.
Total GST activity was quantiﬁed using the CDNB conjuga-
tion assay to assess the level of all GSTs present in H358 and
Figure 9. B[a]PDE-GSH-adducts in H358 and HepG2 cells and media with no TCDD induction. H358 and HepG2 cells were treated with (()-
B[a]PDE for 30 min, 1, 2, 4, and 6 h without TCDD pretreatment for 24 h and GSH-adduct formation quantiﬁed by LC-MS. (A) Intracellular
(()-B[a]PDE-GSH-adducts in H358 cells. (B) Intracellular (()-B[a]PDE-GSH-adducts in HepG2 cells. (C) (()-B[a]PDE-GSH-adducts in H358
cell media. (D) (()-B[a]PDE-GSH-adducts HepG2 cell media. Analyses were conducted in duplicate, and the mean values are shown. (-)-B[a]PDE-
GSH-adduct (solid triangle); (+)-B[a]PDE-GSH-adduct (solid square).
Table 1. GST Activity Levels in H358 and HepG2 Cells
cell samples
GST activity
(nmol/min/mg protein)
H358 (-) TCDD 72026
H358 (+) TCDD 85238
HepG2 (-) TCDD 60637
HepG2 (+) TCDD 17679
Scheme 2. Activation of B[a]P and Detoxiﬁcation of the
Resulting B[a]PDE in Human Lung Cells
a
a TCDD induces P450s 1A1 and 1B1, which activate B[a]P to the reactive
intermediate (+)-B[a]PDE in the lung. This either reacts with dGuo in DNA
to form the (+)-B[a]PDE-dGuo adduct and initiates mutagenesis or is
detoxiﬁed by GST to the (-)-B[a]PDE-GSH-adduct. TCDD induces P450s
1A1 and 1B1 through the AhR to increase the activation of B[a]P. It is
proposed that there is another AhR-mediated interaction, which results in
the increased expression of GSTs that can detoxify (+)-B[a]PDE with high
enantioselectivity. A balance between the activation and detoxiﬁcation
pathways would then determine the amount of DNA damage that occurs.
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expression between lung and liver cells (56). A modest increase
in total GST levels was observed in TCDD-induced H358 cells,
whereas a signiﬁcant decrease in GST activity was observed in
TCDD-induced HepG2 cells (Table 1). Dostal et al. have
reported that the highest afﬁnity for CDNB is GSTR (21), further
suggesting that this GST isoform is not an important mediator
of B[a]PDE-GSH-adduct formation. It is noteworthy that a
recent study was unable to detect any GSH-derived adducts of
B[a]PDE in primary human hepatocytes (46). However, B[a]PDE-
GSH-adducts were not analyzed directly, but the corresponding
N-acetyl-cysteine-adducts were employed as surrogate bio-
markers of GSH-adduct formation. The formation of N-
acetylcysteine-adducts requires γ-glutamyltransferase-mediated
conversion of the GSH-adducts into cysteinylglycine-adducts,
followed by dipeptidase hydrolysis to the cysteine-adducts, and
subsequent N-acetyl transferase-mediated acetylation (45).
Therefore, it is conceivable that the resulting B[a]PDE-N-
acetylcysteine-adducts were not formed in sufﬁcient quantities
by this complex metabolic pathway in order to permit their
detection.
In summary, TCDD-induction of P4501A1/1B1 in lung cells
would be predicted to increase the activation of (-)-B[a]P-7,8-
dihydrodiol to (+)-B[a]PDE resulting in increased DNA damage
when compared with noninduced cells. However, the TCDD
was found to also up-regulate GST-mediated conversion of (+)-
B[a]PDE to (-)-B[a]PDE-GSH-adducts. The increased forma-
tion of nongenotoxic GSH-adducts resulted in decreased amounts
of (+)-B[a]PDE-mediated DNA damage in (()-B[a]PDE-
treated lung cells (Scheme 2). TCDD did not cause any changes
in GSH or GSSG levels (Supporting Information, Figure 1).
This suggests that the increased GSH-adduct formation most
likely occurred through up-regulation of a GST with high
enantioselectivity for (+)-B[a]PDE detoxiﬁcation (26, 48, 49).
Therefore, our data provide compelling evidence that TCDD
can induce the metabolism of (+)-B[a]PDE to a nongenotoxic
GSH-adduct in lung-derived H358 cells most likely through an
AhR-dependent pathway (Scheme 2). It has been proposed that
TCDD/AhR-mediated induction of antioxidant response element
(ARE) driven genes such as GSTs can occur in rodent models
through the Nrf2-Keap1 pathway (43). However, there is no
evidence that human GSTs possess AREs in their noncoding
region, and therefore, it seems unlikely that this mechanism can
explain our ﬁndings. Unfortunately, the majority of GST
induction studies have been conducted in rodent cells (43, 57),
and therefore, the ability of TCDD to regulate the activity of
GSTs in human cells will clearly require substantial additional
studies. It will also be necessary to conﬁrm that our ﬁndings
can be observed in other human lung derived cells. However,
to our knowledge, this is the ﬁrst report that TCDD can induce
GSH-adduct formation in human lung cells and therefore
provides a useful model system with which to pursue further
studies.
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